Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin

被引:22
作者
Hu, Xiaolin [1 ,2 ]
Dong, Mengmeng [2 ]
Liang, Xiao [2 ]
Liu, Ziling [1 ]
Li, Quanshun [2 ]
机构
[1] First Hosp Jilin Univ, Canc Ctr, Changchun 130012, Peoples R China
[2] Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn, Minist Educ, Changchun 130012, Peoples R China
基金
中国国家自然科学基金;
关键词
PEGylated liposomal doxorubicin; hand-foot syndrome; reactive oxygen species; skin lesion; INTRACELLULAR DELIVERY; PATHOGENESIS; DOXIL(R); RELEASE;
D O I
10.2147/IJN.S280187
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: Doxil (PEGylated liposomal doxorubicin, PLD) has been widely used in cancer treatment due to its excellent therapeutic efficacy, but it can simultaneously cause severe adverse effects such as hand-foot syndrome (HFS). To date, the pathophysiologic mechanism of HFS development induced by PLD administration has not been well understood. Materials and Methods: The histological features of skin lesion in PLD-induced HFS model were characterized by hematoxylin and eosin (H&E) staining and picrosirius red staining, and the induction of inflammation and apoptosis in the epidermal layer was detected by immunohistochemical and TUNEL staining. Moreover, the generation of reactive oxygen species (ROS) was determined to elucidate the potential mechanism of skin lesion in the development of HFS. Results: The administration of PLD has been demonstrated to induce the histological damage of skin tissues including the destruction of collagen fibers and the induction of severe inflammation and apoptosis of epidermal cells. The mechanism was probably attributed to the accumulation of PLD in the skin tissues during the long-term circulation and further the induction of ROS to cause the oxidative damage of keratinocytes owing to the sustained release of doxorubicin from PLD. Conclusion: The ROS generation induced by the administration of PLD has been identified to be a crucial factor in the development of HFS, which could be used as a potential therapeutic target to alleviate the HFS symptom of PLD administration.
引用
收藏
页码:471 / 480
页数:10
相关论文
共 29 条
[1]   Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation [J].
Alibolandi, Mona ;
Abnous, Khalil ;
Mohammadi, Marzieh ;
Hadizadeh, Farzin ;
Sadeghi, Fatemeh ;
Taghavi, Sahar ;
Jaafari, Mahmoud Reza ;
Ramezani, Mohammad .
JOURNAL OF CONTROLLED RELEASE, 2017, 264 :228-236
[2]   Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy [J].
Alinnohannnnadi, Reza ;
Alibeigi, Razieh ;
Nikpoor, Amin Reza ;
Chalbatani, Ghanbar Mahmoodi ;
Webster, Thomas J. ;
Jaafari, Mahmoud Reza ;
Jalali, Seyed Annir .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2020, 15 :5279-5288
[3]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[4]   ROS-challenged keratinocytes as a new model for oxidative stress-mediated skin diseases [J].
Barygina, Victoria ;
Becatti, Matteo ;
Lotti, Torello ;
Moretti, Silvia ;
Taddei, Niccolo ;
Fiorillo, Claudia .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (01) :28-36
[5]   Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxA®) [J].
Boers-Sonderen, Marye J. ;
van Herpen, Carla M. L. ;
van der Graaf, Winette T. A. ;
Desar, Ingrid M. E. ;
Arens-van der Logt, Mirjam G. W. ;
de Beer, Yvo M. ;
Ottevanger, Petronella B. ;
van Erp, Nielka P. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) :457-463
[6]   Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish [J].
Chen, Yau-Hung ;
Lee, Ya-Ting ;
Wen, Chi-Chung ;
Chen, Yun-Chen ;
Chen, Yu-Jen .
ONCOTARGETS AND THERAPY, 2014, 7 :1169-1175
[7]   Chronic inflammation deteriorates structure and function of collagen fibril in rat temporomandibular joint disc [J].
Cui, Sheng-Jie ;
Fu, Yu ;
Liu, Yan ;
Kou, Xiao-Xing ;
Zhang, Jie-Ni ;
Gan, Ye-Hua ;
Zhou, Yan-Heng ;
Wang, Xue-Dong .
INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2019, 11 (1)
[8]   New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy [J].
Gabizon, Alberto A. ;
Patil, Yogita ;
La-Beck, Ninh M. .
DRUG RESISTANCE UPDATES, 2016, 29 :90-106
[9]  
Green AE, 2006, INT J NANOMED, V1, P229
[10]   Reassessment of long circulation via monitoring of integral polymeric nanoparticles justifies a more accurate understanding [J].
He, Haisheng ;
Jiang, Sifan ;
Xie, Yunchang ;
Lu, Yi ;
Qi, Jianping ;
Dong, Xiaochun ;
Zhao, Weili ;
Yin, Zongning ;
Wu, Wei .
NANOSCALE HORIZONS, 2018, 3 (04) :397-407